Solid Biosciences Snags Bullish Initiation As It Develops Gene Therapy For Muscular Dystrophy – Benzinga
Benzinga |
Solid Biosciences Snags Bullish Initiation As It Develops Gene Therapy For Muscular Dystrophy
Benzinga The young biotech firm Solid Biosciences Inc (NASDAQ: SLDB) secured two Buy ratings Tuesday and another Wednesday. The Rating. Chardan Capital analyst Gbola Amusa initiated Solid Biosciences with a Buy rating and $40 price target. The Thesis. Amusa … Solid Biosciences Inc. – Common Stock (SLDB) Is Now Covered By Leerink Swann. What can We Expect? Solid Biosciences (SLDB) Coverage Initiated by Analysts at Goldman Sachs Group |
